Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Loperamide + red grapefruit juice refers to a specific drug-food interaction combination evaluated in a Phase 1 clinical trial by Johnson & Johnson Consumer and Personal Products Worldwide. Loperamide is a synthetic oral antidiarrheal and a small molecule mu-opioid receptor agonist that works by slowing intestinal motility. Red grapefruit juice contains compounds that inhibit the intestinal enzyme Cytochrome P450 3A4 (CYP3A4), which is a primary metabolic pathway for loperamide. The interaction study demonstrated that co-administration of red grapefruit juice increases the systemic exposure (AUC) of loperamide by approximately 1.7-fold. Loperamide is also a substrate for the P-glycoprotein efflux transporter, and the study aimed to characterize the pharmacokinetic impact of these interactions in healthy volunteers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on loperamide + red grapefruit juice.